-
Rousey demolishes Carano in MMA comeback fight
-
German 'chemical town' fears impact of industrial decline
-
Qantas flight diverted after man bites flight attendant
-
India scrambles to steady rupee as oil shock bites
-
McGregor to make UFC return with Holloway rematch
-
WHO declares international emergency as Ebola outbreak kills more than 80 in DR Congo
-
Crackdown in Southeast Asia pushes scam networks to Sri Lanka
-
'Geek' hangout to tourist draw: Japan's maid cafes
-
Spacecraft to probe how Earth fends off raging solar winds
-
Bulgaria's 'Bangaranga' wins Eurovision, with Israel second
-
Musk wants SpaceX to go public. Here's how it works
-
Big risks and rewards in upcoming IPOs at SpaceX, OpenAI, Anthropic
-
Pal in last duo could ease nerves for PGA leader Smalley
-
Ronaldo suffers more agony as Al Nassr lose 1-0 in AFC final
-
Venezuela expels Maduro ally Alex Saab to US again
-
Rising star Woad in charge at LPGA Queen City Championship
-
Rodgers returning with Steelers for 22nd season
-
Rahm on PGA: 'It's a battle out there'
-
Dara: dancing to victory at Eurovision
-
As U.S. Markets Continue Surging to Historic All-Time Highs, ELEKTROS Believes This Could Be a Defining Opportunity for Penny Stock Investors Seeking Exposure to the Future of Lithium Mining, EV Infrastructure, and Next-Generation Electrification Technologies
-
Napoleon Solo wins 151st Preakness Stakes
-
Last 10 Eurovision winners
-
Smalley grabs PGA lead as wild final day showdown looms
-
Canada cruise passenger 'presumptive positive' for hantavirus
-
Five share PGA lead logjam with wild final day in store
-
Decision time at full-throttle Eurovision final
-
McIlroy charges into the hunt for epic major comeback win
-
Iran confirms squad heading to Turkey for World Cup preparation
-
Bolivian police clash with protesters blocking roads
-
Eurovision final kicks off with Viennese grandeur
-
Svitolina sees off Gauff to win Italian Open, Sinner in men's title showdown
-
Alonso set for appointment as Chelsea manager: reports
-
Spanish star Javier Bardem says 'narrative changing' on Gaza
-
Gujarat miss out on top spot as Kolkata stay alive in IPL
-
Charging McIlroy grabs share of the PGA lead
-
Rwanda genocide suspect Kabuga dead: court
-
No beer for City stars despite FA Cup win, says Guardiola
-
Modi oversees semi-conductor deal on Dutch trip
-
Americans 'should demonstrate like the French,' says Woody Harrelson
-
Vienna abuzz for Eurovision final
-
McFarlane eyes 'massive' Spurs clash after FA Cup final defeat
-
Scuffles from Europe to NYC as Swatch sale descends into chaos
-
Bielle-Biarrey helps Bordeaux-Begles avoid Top 14 slip-up before Champions Cup final
-
Man City still dream of Premier League glory after FA Cup win: Silva
-
Hearts broken as O'Neill summons Celtic's champion spirit
-
'Dance all night': Harry Styles kicks off World Tour in Amsterdam
-
Kane hits hat-trick, St. Pauli relegated from Bundesliga
-
Semenyo's magic moment fires Man City to FA Cup final win over Chelsea
-
Football back on war-battered pitches in Sudan capital
-
Opposition Latvian lawmaker tapped to form interim government
Baby formula plant linked to US shortage resumes production
Production resumed Saturday at an Abbott Nutrition baby formula plant in the US whose closure helped fuel a crippling nationwide shortage.
The facility in Sturges, Michigan has met initial government sanitary requirements for reopening, the company said in a statement.
The plant shut down in February after the death of two babies, and issued a product recall amid concerns over bacteria contamination.
Shortages of specialized formula were particularly worrying to parents of infants with allergies or with certain metabolic conditions.
Concerns became so acute that President Joe Biden met this week with infant food executives and said his administration was doing everything it could to help.
Abbott said Saturday that it was restarting production of its EleCare formula and that the product should be back on store shelves around June 20.
"We're also working hard to fulfill the steps necessary to restart production of Similac and other formulas," Abbott said.
"We will ramp production as quickly as we can while meeting all requirements."
The United States has been struggling with the shortages for months.
Initially caused by supply chain blockages and a lack of workers due to the pandemic, the shortage was exacerbated when Abbott closed its Sturges plant.
Regulators forced the shutdown amid complaints the plant did not adequately protect against contamination from bacteria.
"Frankly, the inspection results were shocking," FDA chief Robert Califf said last month.
There was standing water in key equipment "that present the potential for bacterial contamination," leaks in the roof and a lack of basic hygiene facilities, he said.
But Abbott officials, while apologizing for the shortage, have said there is no conclusive evidence linking the formula to infant illnesses or deaths.
Abbott's Michigan plant is one of the largest formula factories in the United States.
D.Cunningha--AMWN